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Viewing the pyramid e Through a glass, darkly?‘‘Proof is a conclusion built on a pyramid of
facts, a broad base of accepted information on
which more specific assertions are made. Remove
basic assumptions. Start again. What do we have?’’
Dan Brown. Deception Point. Page 348.
Retsky et al.’s interesting paper1 was posted on
the website of the International Journal of Surgery
on 12th September 2005, publicised by press re-
lease of same date.2 Instantaneous public aware-
ness of this study was achieved across the U.S.
by wide media coverage.
Mammography screening in the 40e49-year-old
age group is an intensely debated topic3: this is
a group of women where a small percentage might
ultimately be affected by indirect evidence from
Retsky et al.’s hypothesis. How should they factor
it into their decision whether to attend, or not?
Also affected by this ‘news’ will be women in
this age group who have invasive cancer who
have had surgery or are about to have surgery.
How worried might they be? How will they inter-
pret it? It is unreasonable to suppose that they
could evaluate the paper itself: it is beyond the
competence of most lay people (including myself
as a ‘lay-person’ breast cancer patient) to grasp
the statistical basis of this paper and put it into
proper perspective, and probably also of many
physicians to whom women might turn for
guidance.
This leads me to question the wisdom of the
process of issuing press releases covering esoteric
research papers that are ‘in press’ on the internet.
It begs the question: is this the right moment to
publicly promote indirect evidence, and is the
media circus the best way of adjudicating these
findings? Better perhaps would be organised mul-
tidisciplinary open debate (including informed lay
people), ideally before it is released to the1743-9191/$ - see front matter ª 2005 Surgical Associates Ltd. P
doi:10.1016/j.ijsu.2005.10.005sensation-hungry media? Indiscriminate publicity
is not necessarily good publicity. Reportage by Amy
Dockser Marcus in the Wall Street Journal4 was the
exception rather than the rule: it offered welcome
critical appraisal of Retsky et al.’s findings, in
contrast to the majority of the 52 irresponsible
U.S. media reports known to me. Sensationalised
press reports and headlines using extravagant lan-
guage are likely to have caused fear, or even
avoidance of surgery.5 This does not serve the
women it was intended to help. Rational appraisal
of the strength of this indirect evidence, clarifi-
cation about the proportion of women it would
be likely to affect, and determination to explore
remaining uncertainties (as suggested by the
authors) would have been less damaging and
more constructive.
Retsky et al.’s findings align with earlier hypo-
theses and findings about the deleterious effect of
surgery perturbing distant dormant disease.6 They
suggest why recurrence for women with breast
cancer is highest in the first two years, particularly
for the 40e49 year olds. They could also explain
the counterintuitive finding why, in this age group
in the mammography arm of the Canadian trial,
there was unexplained temporary excess in mor-
tality compared with that in the control arm.7
Retsky et al. recommend that, at the very least,
women need to be advised of this information as
part of an informed consent to mammography.
How it should be weighted into decisions is open
for discussion.
How then might this group of women (and,
indeed, all groups) be assisted to make reasoned
and rational decisions with their physicians so that
they can give un-pressured informed consent
for screening? The individual decision-making pro-
cess should be based on a very individualised
appreciation of probability, including the a prioriublished by Elsevier Ltd. All rights reserved.
Editorial 241likelihood of being susceptible to the condition,
and all other known relevant risk factors. Women
and their physicians need constantly updated reli-
able evidence to factor into their decision, as
appropriate. Those women who seek further in-
formation to supplement the inadequate, fre-
quently coercive information issued by providers,
will be hard-pushed to find it.8
The public do not readily appreciate that the
harms of screening are not necessarily those from
the test itself, but from interventions which might
follow.9 Any suspicion of an abnormality will lead
to further tests and/or interventions, quite often
including surgery. Inaction is rare10: watchful wait-
ing brings its own harmful anxieties.
The statement that women differ in their
physical make-up cannot be denied: perhaps this
fact is becoming more generally appreciated? New
evidence in 2003 about hormone replacement
therapy (HRT) upset pre-conceived notions about
its respective benefits and harms in individual
categories of women.11 Media reports could have
been educative for the public, but usually caused
confusion instead.12 Current media reports about
use of Herceptin could also have illustrated this
diversity of individual response by clearer explana-
tion. These reports could have emphasised that all
patients will need to be tested for expression of
HER2/neu to find the twenty or so out of a hundred
possibly suitable for prescription of trastuzumab
(Herceptin). They could also have warned (as
should breast screening providers) that the test is
only 80% accurate, and will produce false positives
and false negatives resulting in over- and under-
treatment. ‘‘Mighty media campaigns’’ for this
latest ‘breakthrough’ drug are driving its un-
tempered supply and demand. As do politicians
who state that they want to see the drug ‘‘in wide-
spread use’’, many months before it will get
a licence.13
Women need to know that breast cancer is
a heterogeneous disease; that age is the major
risk factor; that individual biological make-up will
affect a woman’s chances of getting breast cancer;
her likely response to surgery, chemotherapy and
radiotherapy14; and her chance of benefiting. As-
sessing all those factors is not easy: interpreting
and understanding them is even more difficult. Sur-
veys have shown how women grossly overestimate
their risks,15 and that the psychological impact of
DCIS is as great as that for an invasive cancer.16 Per-
ception of risk is not a purely rational matter,17
particularly when influenced by over-estimations;
fear; prevailing culture; media sensationalism and
the defensive ripostes of professional proponents
of mammographic screening for 40 year olds.18Communication of risk is a skilled task and one vital
to the decision-making process.19
Let us take up Retsky et al.’s recommendations
to undertake further research to confirm the
veracity of their findings, and design clinical trials
to address related questions. Constructing a firm
foundation of causality and evidence to support
both policy recommendations and women’s deci-
sions whether to present for screening or not
requires constant review, astute observation in
basic sciences, multidisciplinary scientific exper-
tise, and imagination on the part of investigators.
It also requires reasoned, rational responses from
policy makers, the medical community, the media
and the general public, rather than the usual
dismissive reactions.20 This approach could help
to ultimately achieve women’s decisions that
might more truly be described as ‘informed’.
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